Pharma News

CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email March 19, 2024
0 124,535 Less than a minute

CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension.

Source link
#CST2140 #CuraSen #Therapeutics #Orthostatic #Hypotension #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email March 19, 2024
0 124,535 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *